BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense. Alloy has exclusively licensed IP underlying the AntiClastic ASO platform from Sudhir Agrawal’s Arnay Sciences LLC.
Read more here.
![[IQM in Business Wire] IQM: Unimon – a new qubit to boost quantum computers for useful applications](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
